Inotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemia.

Item

http://www.wikidata.org/entity/Q38984055

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Inotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemia.

@en

type

Item

label

Inotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemia.

@en

prefLabel

Inotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemia.

@en

P1476

Inotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemia

@en

P2093

Anjali Advani

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2016

Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study.

Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma.

Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab.

A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma.

FDA Approval: Blinatumomab.

Long-term follow-up of the United Kingdom medical research council protocols for childhood acute lymphoblastic leukaemia, 1980-2001

Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody.

Feasibility of allografting in patients with advanced acute lymphoblastic leukemia after salvage therapy with inotuzumab ozogamicin.

Understanding and exploiting nature's chemical arsenal: the past, present and future of calicheamicin research.

P304

425-434

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/EJH.12862

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Swapna Thota

P577

2017-03-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28152223

http://www.w3.org/2001/XMLSchema#string